Add BrightSurf on Google Email

CityU research estimates vaccine donation from high to low- and middle-income countries will help end COVID-19 pandemic

A team led by City University of Hong Kong researcher Dr Zhang Qingpeng found that donating 46% to 80% of COVID-19 vaccines to low- and middle-income countries can significantly reduce infection rates and mortality. The study suggests prioritizing vaccines for countries with high incidence, prevalence, and mortality rates.

SourceCity University of Hong Kong·JournalNature Human Behaviour·TypeData/statistical analysis·DateMar 1, 2022

Does severe COVID-19 affect pregnancy outcomes?

A recent study published in Acta Obstetricia et Gynecologica Scandinavica has found that severe COVID-19 in pregnancy is associated with a higher risk of adverse outcomes, including preterm birth and stillbirths. The research highlights the importance of vaccination against severe disease to protect both mothers and babies.

SourceWiley·JournalActa Obstetricia Et Gynecologica Scandinavica·DateFeb 24, 2022

The Lancet Child & Adolescent Health: Multi-system inflammatory syndrome in children (MIS-C) is rare among 12- to 20-year-olds who have received COVID-19 vaccination, study suggests

A study published in The Lancet Child & Adolescent Health found that reported cases of multi-system inflammatory syndrome (MIS-C) in children and adolescents who had received at least one COVID-19 vaccine dose were rare. Only one case was estimated per million vaccinated individuals in this age group, according to the CDC.

SourceThe Lancet·JournalThe Lancet Child & Adolescent Health·TypeObservational study·DateFeb 22, 2022

Study looks at Moderna COVID-19 vaccine effectiveness

A Kaiser Permanente study published in Nature Medicine found that three doses of the Moderna COVID-19 vaccine were highly effective against hospitalization caused by infection from either the omicron or delta variant. The research suggests that third doses may be needed sooner than previously thought to protect against omicron infectio...

SourceKaiser Permanente·JournalNature Medicine·DateFeb 22, 2022

Omicron variant: surgery and anaesthesia experts issue update on timing of elective surgery following emergence of omicron variant of SARS-CoV-2

Experts recommend individualised multidisciplinary risk assessment for patients requiring elective surgery within 7 weeks of SARS-CoV-2 infection, considering baseline mortality risk calculation and surgical factors. Patients with persistent symptoms or moderate to severe COVID-19 may require longer delays than 7 weeks.

SourceAAGBI·JournalAnaesthesia·DateFeb 22, 2022

Risk of second allergic reaction to SARS-CoV-2 vaccines

A systematic review and meta-analysis found that the risk of immediate allergic reactions to a second dose of SARS-CoV-2 mRNA vaccines is low among patients who experienced an immediate allergic reaction to their first dose. The study included 1,366 patients and showed no significant increase in severe immediate reactions or anaphylaxis.

SourceJAMA Network·JournalJAMA Internal Medicine·DateFeb 21, 2022

T-cell responses may help predict protection against SARS-CoV-2 infection in individuals with and without cancer

New study reveals that T-cell responses against the SARS-CoV-2 spike protein can predict protection against infection. In healthy individuals, T cells with a specific cytokine profile offered immunity against COVID-19. In contrast, cancer patients showed lower T-cell responses and increased susceptibility to infection.

SourceAmerican Association for Cancer Research·JournalCancer Discovery·DateFeb 18, 2022

‘Prescribe ivermectin for COVID-19 only in large-scale randomized trials’

Researchers from Florida Atlantic University advise against prescribing ivermectin to treat or prevent COVID-19 due to the lack of reliable evidence. They emphasize the importance of relying on proven therapeutic innovations and vaccinations to combat the pandemic, citing the risks of unproven treatments like ivermectin.

SourceFlorida Atlantic University·JournalTherapeutic Innovation & Regulatory Science·TypeCase study·DateFeb 16, 2022

A potentially longer-lasting cholera vaccine

Researchers have created a new type of cholera vaccine consisting of polysaccharides displayed on virus-like particles, generating long-lasting antibody responses in mice. The vaccine shows promise as a next-generation cholera vaccine, potentially replacing current vaccines that last only 2-5 years.

SourceAmerican Chemical Society·JournalACS Infectious Diseases·DateFeb 16, 2022

Increased infectivity, antibody escape drive SARS-CoV-2 evolution, studies say

Researchers analyzed over 1.5 million SARS-CoV-2 genome sequences to understand the evolution of the virus, finding that increased infectivity is a driving force behind its spread. The omicron variant is predicted to compromise current vaccines and therapies, highlighting the need for new generation of vaccines and monoclonal antibodies.

SourceAmerican Chemical Society·JournalACS Infectious Diseases·DateFeb 16, 2022

UH sociologist finds disparities in initial COVID-19 vaccine distribution

A new study by University of Houston sociologist Kathryn Freeman Anderson reveals significant disparities in the initial COVID-19 vaccine rollout in five urban Texas counties. The research found that Black and Latino neighborhoods were less likely to receive vaccines due to existing healthcare resource shortages.

SourceUniversity of Houston·JournalJournal of Health and Social Behavior·TypeMeta-analysis·DateFeb 15, 2022

3 doses of Pfizer–BioNTech COVID vaccine better than 2

A Kaiser Permanente study found that a third dose of the Pfizer-BioNTech COVID-19 vaccine significantly improved protection against severe disease, hospitalization, and death. The study's results suggest that three doses of the vaccine provide greater benefit than two doses in preventing these outcomes.

SourceKaiser Permanente·JournalThe Lancet Regional Health - Americas·DateFeb 14, 2022

Study finds previous COVID-19 infection, but not vaccination, improves performance of antibodies and potentially provides longer-term protection

A study found that previous COVID-19 infection improves the performance of antibodies and potentially provides longer-term protection, especially in obese individuals. In contrast, vaccination does not enhance antibody quality and may not provide sustained immunity in those who have been previously infected or overweight.

Proportion of women reporting side-effects after the 1st, 2nd or 3rd dose of the Pfizer vaccination almost twice (1.9 times) that among men

A recent study published in Vaccines found that the proportion of women reporting side-effects after Pfizer vaccinations is almost twice that of men. The highest frequencies of side-effects were reported after the second vaccination, with pain in the entire arm and weakness being notable examples.

SourceUniversity of Haifa·JournalVaccines·DateFeb 10, 2022

Biologists isolated the coronavirus nucleoprotein in its pure form to improve the accuracy and sensitivity of the antibody tests

Biologists isolated the SARS-CoV-2 nucleoprotein in its pure form to create more accurate antibody tests. The new approach significantly improves sensitivity, increasing the ability to detect antibodies to the nucleoprotein. This breakthrough helps determine if vaccinated individuals have been infected with COVID-19.

Vaccine protection against SARS-CoV-2 infection wanes quickly but is better maintained against severe disease

A nationwide study in Sweden found that vaccine-induced protection against SARS-CoV-2 infection decreases over time, with most protection lost within seven months. However, protection against severe COVID-19 remains relatively stable, suggesting that booster shots may be necessary to maintain effectiveness.

SourceUmea University·JournalThe Lancet·TypeData/statistical analysis·DateFeb 7, 2022

Spanish-language vaccine resources harder to access, while Hispanic vaccination rates remain below overall average, study finds

A study found that many big box retailers lack Spanish language COVID-19 vaccine resources, hindering access for Hispanic populations. The researchers recommend increasing the visibility of these resources and incorporating non-English materials into public health strategies.

SourceUniversity of Chicago Medical Center·JournalJournal of General Internal Medicine·DateFeb 4, 2022

Harvard Chan research shows actions to prevent pandemics cost 5% of lives lost every year from emerging infectious diseases

Researchers provide cost-effective actions to prevent pandemics, including better surveillance and wildlife management, with estimated annual costs under $20 billion. These 'primary pandemic prevention' actions can help prevent future pandemics and have substantial co-benefits for human health, environment, and economic development.

SourceHarvard Chan C-CHANGE·JournalScience Advances·DateFeb 4, 2022

Research shows actions to prevent pandemics cost 5% of lives lost every year from emerging infectious diseases

A new study suggests that implementing primary pandemic prevention actions, such as better surveillance and wildlife management, can reduce the economic costs of emerging infectious diseases by up to 10%. These actions have a substantial co-benefit of preventing carbon dioxide emissions and conserving water supplies.

SourceHarvard T.H. Chan School of Public Health·JournalScience Advances·TypeMeta-analysis·DateFeb 4, 2022

Immunotherapy with house dust mite extract reduces symptoms of atopic dermatitis

Researchers found sublingual immunotherapy with house dust mite extract to be effective in reducing signs and symptoms of atopic dermatitis. The treatment, administered over 18 months, resulted in significant improvements in pruritus and lesions, with rare side effects.

SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalJournal of Allergy and Clinical Immunology: In Practice·TypeRandomized controlled/clinical trial·DateFeb 3, 2022

First U.S. peer-reviewed study on omicron patient outcomes reveals rapid spread and significant differences in infection behavior

The first US peer-reviewed study on omicron patient outcomes found significant differences in infection behavior. Ominron patients are significantly younger, have increased vaccine breakthrough rates, and are less likely to be hospitalized compared to patients with alpha or delta variants.

SourceHouston Methodist·JournalAmerican Journal Of Pathology·TypeData/statistical analysis·DateFeb 3, 2022

Study predicts that routine immunisation with the first typhoid conjugate vaccine (TCV) could avert 46-74% of typhoid fever cases

A mathematical modeling study predicts that routine immunization with TCV could avert 46-74% of all typhoid fever cases in 73 countries. Vaccination is also expected to reduce the relative prevalence of antimicrobial-resistant typhoid by 16%, preventing millions of cases and deaths.

SourceCenter for Disease Dynamics, Economics & Policy·JournalThe Lancet Infectious Diseases·TypeComputational simulation/modeling·DateFeb 3, 2022